



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



## TP63 Rearrangement

### Alternative Name

TBL1XR1/TP63

### Methodology

FISH

### Test Description

**Probes:** TP63 (3q28) | TBL1XR1/TP63 [inv(3)(q26q28)]

**Disease(s):** Anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma (PTCL)

**Note:** Probes are not orderable separately; concurrent analysis is necessary due to proximity of breakpoints in the most common fusion rearrangement.

### Clinical Significance

TP63 gene rearrangements encoding p63 fusion proteins define a subset of ALK-negative anaplastic large cell lymphoma (ALCL) cases and are associated with aggressive course and poor outcome compared to peripheral T-cell lymphoma (PTCL) cases without these rearrangements. This test includes targeted analysis for the TBL1XR1/TP63 fusion, which has also been reported in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Positive results will be reported for this fusion or TP63 gene rearrangement with another partner not identified by this assay.

### Specimen Requirements

- **Bone Marrow Aspirate:** N/A
- **Peripheral Blood:** N/A
- **Fresh, Unfixed Tissue:** N/A
- **Fluids:** N/A
- **Paraffin Block:** H&E slide (required) plus paraffin block. Circle H&E for tech-only.
- **Cut Slides:** H&E slide (required) plus 2 unstained slides cut at 4 microns. Circle H&E for tech-only.

### Storage & Transportation

Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

88377x2 manual or 88374x2 automated

### New York Approved

Yes

### Level of Service

Global, Technical

## Turnaround Time

3-5 days

## References

1. Pedersen MB et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*. 2017;130:554-557.
2. Parrilla Castellar ER et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*. 2014;124:1473-80.
3. Vasmataz G et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood*. 2012;120:2280-2289.
4. Scott DW et al. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphomas. *Blood*. 2012;119:4949-4952.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 112224